← Eichor
Study identifier: NCT06593964 Synced from ClinicalTrials.gov · July 27, 2026
● Recruiting

TACE With Thermosensitive Nanogel Versus Embosphere for HCC

Condition: Unresectable Hepatocellular Carcinoma  ·  Sponsor: Zhongda Hospital

PhaseNA
Planned participants188
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.

This description comes directly from the study's public registry record.

Talk to the study team

Lei Zhang, M.D.  ·  +86 13770106862  ·  llei589@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Gao-Jun TengNanjing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06593964